^
    Back
    Association details:
    Biomarker:HER-2 N857S
    Cancer:Ovarian Cancer
    Drug:lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib

    Excerpt:
    Summary of ERBB2 mutants analyzed along with the IC50 values against reversible inhibitors lapatinib and AEE788....ERBB2-N857S (IC90 approximately 0.5 µM) mutations might respond to higher doses of lapatinib…For lapatinib-sensitive mutations(IC50 value between 30 nM and 1 µM).
    DOI:
    10.1371/journal.pone.0026760